JKT · SRAJ.JK
PT Sejahteraraya Anugrahjaya Tbk
IDR 10,850-IDR 125 (-1.14%)
PT Sejahteraraya Anugrahjaya Tbk’s quoted price sits in the lower half of its reported 52-week range, 43.49% below the high.
Loading market information…
JKT · KLBF.JK · IDR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:35 AM UTC. Cached market data; not a live quote.
One-year closing-price history · IDR. Historical prices are not a forecast.
PT Kalbe Farma Tbk.’s quoted price sits in the lower half of its reported 52-week range, 44.4% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
PT Kalbe Farma Tbk.’s forward annual dividend is IDR 20 per share, paid annual. The forward yield is 2.68% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
PT Kalbe Farma Tbk.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of IDR 17. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PT Kalbe Farma Tbk.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PT Kalbe Farma Tbk., an Indonesian pharmaceutical leader, along with its subsidiaries, focuses on the development, manufacturing, and commercialization of pharmaceutical products across Indonesia. Its operations are structured into four primary divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution & Logistics. The company's diverse portfolio encompasses generic, branded, and licensed medications, including well-known names like Brainact, Cefspan, and Mycoral, which are supplied to hospitals, pharmacies, and various drugstores. Beyond prescription drugs, it offers non-prescription medicines, a range of energy and ready-to-drink beverages, dietary supplements, and other preventive health solutions. Kalbe Farma also produces specialized nutritional products tailored for all demographics, from infants to seniors, including expectant mothers and individuals with specific medical dietary needs. The firm extends contract services to other pharmaceutical companies, covering clinical study management, bioavailability/bioequivalence assessments, and analytical testing. Additionally, it provides animal health products and operates its own healthcare facilities, the Mitrasana Clinics. Its broad scope of activities further includes health screening, acting as an agent for biotechnology products, and the distribution of consumer items, medical devices, and cosmetics. The company also trades in medical and laboratory equipment and supplies, raw materials for pharmaceuticals, and consumables for hemodialysis therapy, in addition to offering advertising services. Founded in 1966, PT Kalbe Farma Tbk. is headquartered in Jakarta, Indonesia.
Latest available per-share figures in IDR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2024 | Mar 28, 2025 | IDR 17+3.43% vs estimate | IDR 8.39T-0.25% vs estimate |
|---|
| Q3 2024 | Oct 30, 2024 | IDR 12-28.1% vs estimate | IDR 7.91T0.0% vs estimate |
|---|
| Q2 2024 | Jul 30, 2024 | IDR 18+7.49% vs estimate | IDR 7.97T+9.64% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
IDR 10,850-IDR 125 (-1.14%)
PT Sejahteraraya Anugrahjaya Tbk’s quoted price sits in the lower half of its reported 52-week range, 43.49% below the high.
IDR 1,915+IDR 15 (+0.79%)
PT Siloam International Hospitals Tbk’s quoted price sits in the lower half of its reported 52-week range, 33.51% below the high.
IDR 1,115-IDR 45 (-3.88%)
PT SOHO Global Health Tbk.’s quoted price sits in the lower half of its reported 52-week range, 72.19% below the high.
IDR 2,410-IDR 80 (-3.21%)
PT Tempo Scan Pacific Tbk’s quoted price sits in the lower half of its reported 52-week range, 25.16% below the high.
IDR 338-IDR 20 (-5.59%)
PT Kimia Farma (Persero) Tbk’s quoted price sits in the lower half of its reported 52-week range, 56.94% below the high.
IDR 1,570IDR 0 (0.0%)
PT Darya-Varia Laboratoria Tbk’s quoted price sits in the upper half of its reported 52-week range, 7.37% below the high.
IDR 3,600-IDR 10 (-0.28%)
PT Merck Tbk’s quoted price sits in the lower half of its reported 52-week range, 20.0% below the high.
IDR 133-IDR 9 (-6.34%)
PT Pyridam Farma Tbk’s quoted price sits in the lower half of its reported 52-week range, 78.72% below the high.
